ReviewCancer control : journal of the Moffitt Cancer Center2012
Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.
Review in Cancer control : journal of the Moffitt Cancer Center, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Trial
- Presence of herpesviruses, parvoviruses, and polyomaviruses in sinonasal lymphoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Article
- Article
- Tackling Mantle Cell Lymphoma in Europe.Healthcare (Basel, Switzerland) · 2022Article
- Mantle cell lymphoma with aseptic meningitis mimicking hydrocephalus on brain imaging.Nagoya journal of medical science · 2022Article
- Article
- Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States.Journal of managed care & specialty pharmacy · 2022Article
- Clinicopathologic Features and Treatment of CD10-Positive Mantle Cell Lymphoma: A Case Report and Review of Literature.Pathology oncology research : POR · 2022Review
- Article
- Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.European journal of haematology · 2021Article
- Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.Nature communications · 2021Article
- Article
- Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.Current oncology (Toronto, Ont.) · 2019Review
- A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma.Frontiers in oncology · 2019Article
- Inhibition ofMolecular cancer therapeutics · 2018Article
- The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.BMC cancer · 2016Observational
- BCL-1 Gene Rearrangements in Iranian Non-Hodgkin Lymphoma Patients.Global journal of health science · 2016Article
- Histone Modifications and Cancer.Cold Spring Harbor perspectives in biology · 2016Review
- A case of mantle cell lymphoma presenting with ascites.Clinical case reports · 2016Article
- A Rare Manifestation of a Rare Disease: Mantle Cell Lymphoma Presenting With Aseptic Meningitis.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMantle cell lymphoma (MCL) remains incurable using conventional chemotherapeutic approaches. New clinical data show that some patients have a chronic/indolent course and others have a more fulminant course and short survival, similar to that of patients with acute leukemias.
methodsThis review presents an overview of this aggressive disease, including the diagnosis, epidemiology, prognosis, and management of this protean and challenging condition.
resultsDistinguishing indolent MCL from in situ MCL is important but can be challenging. Molecular exploration has identified SOX11 and HDAC11 as potential candidate genes for discrimination of indolent cases. Improvements in the prognosis in MCL are likely the result of earlier identification of more indolent cases and the application of modern modalities, including rituximab and autologous transplantation. Younger patients may be able to tolerate more intensive therapy, while treatment for elderly or frail patients may focus on maintenance to prolong remission. For patients with relapsed disease, some agents have shown promise, such as lenalidomide and bortezomib. Emerging drugs such as PCI37625 and CAL-101 are being explored in phase I and II studies.
conclusionsAlthough patients with MCL continue to experience poor outcomes, new treatment approaches for various stages of disease are showing promise in improving survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.